This conversion of IL-4 signaling inhibition into a signal that amplifies the antitumor efficacy of CAR–T cells at the tumor site (signal 3-stimulatory cytokine signaling) serves to safeguard CAR–T cells against cytokine-mediated suppression. Here, IL4 is linked to neoplasm.